{"id":"W2270737067","doi":"10.1200/jco.2009.27.15_suppl.e15634","title":"A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"","keywords":"Eribulin; Medicine; Gemcitabine; Internal medicine; Gastroenterology; Neutropenia; Pancreatic cancer; Progressive disease; Oncology; Adverse effect; Cancer; Metastatic breast cancer; Toxicity; Surgery; Chemotherapy; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008972731,0.001185256,0.001919518,0.0004199801,0.000349179,0.0007214851,0.0007470349,0.001078163,0.004698584],"category_scores_gemma":[0.0004378713,0.000460912,0.000843031,0.0004426472,0.0005712117,0.0005751314,0.0002675644,0.002128757,0.001002265],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006627732,"about_ca_system_score_gemma":0.001258034,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007824092,"about_ca_topic_score_gemma":0.002072806,"domain_scores_codex":[0.9997427,0.0001294411,0.00001383925,0.00003673238,0.00002357317,0.0000536817],"domain_scores_gemma":[0.9996495,0.0000507021,0.00005717692,0.00002959944,0.00002437005,0.0001885596],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5512331,0.1667808,0.01164559,0.001277973,0.001138824,0.0008728405,0.0004657243,0.003952196,0.1169308,0.0004693687,0.005544554,0.1396881],"study_design_scores_gemma":[0.4791919,0.4977146,0.01184002,0.00003740473,0.0002491557,0.0005404848,0.00007762808,0.001397467,0.005451488,0.000143278,0.003335078,0.00002148895],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921409,0.000994399,0.0005159806,0.0002827281,0.00009267517,0.003783441,0.0007476765,0.0000629745,0.00137913],"genre_scores_gemma":[0.9856448,0.001646232,0.002023892,0.0007375139,0.0001326752,0.004149599,0.002155715,0.0000263498,0.003483278],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004698584,"threshold_uncertainty_score":0.01571828,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08946331562877648,"score_gpt":0.5214411670188722,"score_spread":0.4319778513900958,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}